Avalo Therapeutics 3Q 2026: EPS ($0.34) — 10-Q Summary

What happened

Avalo Therapeutics reported a third-quarter 2026 net loss of $18.95 million, compared with $30.63 million a year earlier, while diluted loss per share narrowed to $0.34 from $2.19. Higher research and administrative costs were more than offset by improved other income, including higher interest income and a favorable change in derivative liability value.

Confirmed

Global impact / market context

The narrower loss points to improved reported results, but it did not come from lower operating costs: research and development and administrative expenses rose. That distinction matters because continued spending on clinical programs can use cash even as accounting losses improve through other income.

Analyst inference

Avalo said it had $462.8 million in cash, cash equivalents and investments at September 30, 2026, and expects this to fund operations into 2029. That provides a stated runway for development, while clinical progress and spending levels remain relevant to future funding needs.

Confirmed

What to watch

1. Track whether research and development costs remain elevated as Avalo prepares abdakibart for a Phase 3 program and develops AVTX-010, its long-acting antibody candidate. Analyst inference
2. Watch for updates on abdakibart’s progress toward a Phase 3 registrational program in hidradenitis suppurativa, a chronic inflammatory skin disease. Confirmed
3. Compare future cash and investment balances with the stated expectation of funding operations into 2029; faster spending could shorten that expected runway. Analyst inference

Evidence

• Original source link unavailable